Inhibrx Biosciences, Inc. (INBX) Form 8-K — Aug 13, 2026
Inhibrx Biosciences reported second quarter 2026 financial results on August 13, 2026, posting a net loss of $36.7 million, or $2.34 per share, versus a net loss of $28.7 million, or $1.85 per share, in the year-ago quarter, and recognized no revenue compared with $1.3 million of license fee revenue in Q2 2025. Cash and cash equivalents were $133.3 million at June 30, 2026. After drawing $100.0 million in July under a second amendment to its loan agreement with Oxford Finance that provides up to $325.0 million in additional gross proceeds, the company held $219.5 million as of August 6, 2026.
Key figures
- Revenue
- 0
- Total Debt
- 175000000
- Debt Amount
- 325000000
- Total Assets
- 154222000
- Cash Position
- 133344000
- Pdufa goal date
- April 14, 2027
- Q2 2025 revenue
- 1300000
- Cash august 6 2026
- 219500000
- Long term debt net
- 176285000
- Q2 2025 gna expense
- 6422000
- Q2 2025 rnd expense
- 22267000
- Q2 2026 gna expense
- 8250000
- Q2 2026 rnd expense
- 23899000
- Oxford funded july 2026
- 100000000
- Q2 2025 other expense net
- 1263000
- Q2 2026 other expense net
- 4498000
- Shares used in eps q2 2026
- 15669000
- Oxford discretionary increment
- 225000000
- Oxford amendment gross proceeds total
- 325000000
Price after filing
Close on the filing date to close N calendar days later (from $92.38). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.